主观认知下降患者中轻微神经心理缺陷的相关性
本研究基于DZNE纵向认知障碍与痴呆观察性研究,纳入临床主观认知下降(SCD)患者及无SCD的健康对照,基线有脑脊液和/或纵向认知数据。结果显示,SCD伴轻微神经心理缺陷(MNPD)者脑脊液阿尔茨海默病生物标志物更异常、认知下降更显著、进展为轻度认知障碍(MCI)风险更高(HR 4.07,95%CI 2.46-6.74)。
要点
- SCD伴MNPD者进展为MCI风险显著高于不伴MNPD者(HR 4.07,95%CI 2.46-6.74)。
- MNPD对SCD 3年内进展为MCI的阳性预测值为57.0%,阴性预测值为86.0%。
- 不伴MNPD的SCD者较健康对照仍有更高的MCI风险(HR 4.09,95%CI 2.07-8.09)。
核心结论
- 作者认为,MNPD是寻求医疗咨询的认知正常SCD患者中AD相关临床进展的风险因素。
- 作者认为,MNPD评估可能有助于个体临床预测和临床试验中的AD风险分层。
- 作者指出,即使没有MNPD,SCD仍是未来认知下降的风险因素。
研究设计与样本
- 研究纳入来自观察性DZNE纵向认知障碍与痴呆研究的临床SCD患者及无SCD的健康对照,基线有脑脊液和/或纵向认知数据。
- MNPD定义为在人口学调整的阿尔茨海默病登记联盟神经心理评估成套测验总分上至少低于均值0.5个标准差。
- 样本共672人,平均年龄70.7±5.9岁,女性占50%;SCD伴MNPD者55人(占SCD组的12.5%),SCD不伴MNPD者384人,健康对照不伴MNPD者215人。
- 随访时间均值±标准差为40.6±23.7个月。
主要发现
- SCD伴MNPD者较SCD不伴MNPD者脑脊液生物标志物水平更异常、认知下降更显著、进展为MCI风险更高(HR 4.07,95%CI 2.46-6.74)。
- MNPD对SCD 3年内进展为MCI的阳性预测值为57.0%(95%CI 38.5-75.4),阴性预测值为86.0%(95%CI 81.9-90.1)。
- SCD不伴MNPD者较健康对照不伴MNPD者认知下降更显著、MCI风险更高(HR 4.09,95%CI 2.07-8.09),但两组AD生物标志物水平无显著差异。
临床怎么用
- 作者认为,MNPD评估可能有助于个体临床预测和临床试验中的AD风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To determine the relevance of minor neuropsychological deficits (MNPD) in patients with subjective cognitive decline (SCD) with regard to CSF levels of Alzheimer disease (AD) biomarkers, cognitive decline, and clinical progression to mild cognitive impairment (MCI). METHODS: This study included patients with clinical SCD and SCD-free, healthy control (HC) participants with available baseline CSF and/or longitudinal cognitive data from the observational DZNE Longitudinal Cognitive Impairment and Dementia study. We defined MNPD as a performance of at least 0.5SD below the mean on a demographically adjusted total score derived from the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery. We compared SCD patients with MNPD and those without MNPD with regard to CSF amyloid-β (Aβ)42/Aβ40, phosphorylated tau (p-tau181), total tau and Aβ42/p-tau181 levels, longitudinal cognitive composite trajectories, and risk of clinical progression to incident MCI (follow-up M ± SD: 40.6 ± 23.7 months). In addition, we explored group differences between SCD and HC in those without MNPD. RESULTS: In our sample (N = 672, mean age: 70.7 ± 5.9 years, 50% female), SCD patients with MNPD (n = 55, 12.5% of SCD group) showed significantly more abnormal CSF biomarker levels, increased cognitive decline, and a higher risk of progression to incident MCI (HR: 4.07, 95% CI 2.46-6.74) compared with SCD patients without MNPD (n = 384). MNPD had a positive predictive value of 57.0% (95% CI 38.5-75.4) and a negative predictive value of 86.0% (95% CI 81.9-90.1) for the progression of SCD to MCI within 3 years. SCD patients without MNPD showed increased cognitive decline and a higher risk of incident MCI compared with HC participants without MNPD (n = 215; HR: 4.09, 95% CI 2.07-8.09), while AD biomarker levels did not differ significantly between these groups. DISCUSSION: Our results suggest that MNPD are a risk factor for AD-related clinical progression in cognitively normal patients seeking medical counseling because of SCD. As such, the assessment of MNPD could be useful for individual clinical prediction and for AD risk stratification in clinical trials. However, SCD remains a risk factor for future cognitive decline even in the absence of MNPD.
引用
- Stark M, Wolfsgruber S, Kleineidam L, et al. Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline. Neurology. 2023. PMID: 37821235. doi:10.1212/WNL.0000000000207844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。